Hi Luis, one thing to keep in mind is that this stock has the typical biotech pattern of going up as the time for test results approach. This 6 month in advance of the results is a bit early. Somewhere in here, unless we get news of someone buying up the stock (when they go over 5%), we will get a trading range with occassional dips. If it turns out someone is buying, then the trading range might be higher.
What I am getting at is that a couple of months before they release the phase 3 data, one might consider accumulating more shares. When they announce they have finished the study, it will take them 1-3 months to tabulate the data. My guess is there will a slow increase in price, to be safe, think about selling some just before the anticipated news release. I think the high will be around here unless the news is so great that one might buy back the shares.
I like the drug, but this is also a biotech company, so caution for this type of speculation helps. One good thing is that investor relations has really shaped up. They actually understand what is going on, a first!. |
